Planet Fitness To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst…
Top 4 Health Care Stocks That May Crash This Month
As of Dec. 20, 2023, four stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Insiders Buying Pfizer And 3 Other Stocks
Although U.S. stocks closed higher on Tuesday, there were a few notable insider trades.
Why Quanex Building Products Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Friday’s Mid-Day Session
Shares of Quanex Building Products Corporation (NYSE: NX) moved lower during Friday’s session after the company reported fourth-quarter financial results.
Quanex Building Products shares fell 10.7% to $30.95 on Friday.
12 Health Care Stocks Moving In Friday’s Intraday Session
Gainers Virpax Pharmaceuticals (NASDAQ:VRPX) stock rose 57.8% to $0.38 during Friday’s regular session. The market value of their…
Why Is Skin Disease-Focused Verrica Pharmaceuticals Stock Trading Higher Today?
Verrica Pharmaceuticals Inc's (NASDAQ: VRCA) development and commercialization partner, Torii Pharmaceutical Co Ltd, reported topline results from its Phase 3 trial of TO-208 (referred to as VP-102 and marketed as Ycanth in the U.S.) for the treatment of Molluscum
12 Health Care Stocks Moving In Friday’s Pre-Market Session
Gainers Heart Test Laboratories (NASDAQ:HSCS) stock rose 27.1% to $0.2 during Friday’s pre-market session. The company’s market cap…
Earnings Scheduled For November 9, 2023
Companies Reporting Before The Bell
• Indivior (NASDAQ:INDV) is expected to report quarterly earnings at $0.30 per share on revenue of $265.00 million.
7 Analysts Have This to Say About Verrica Pharmaceuticals
Within the last quarter, Verrica Pharmaceuticals (NASDAQ:VRCA) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat…
Verrica Pharmaceuticals Announces Presentation Of Lesion Clearance Data From An Ongoing Phase 2 Study Of VP-315 For The Treatment Of Basal Cell Carcinoma At The American Academy Of Dermatology 2023 Innovation Academy Meeting
Presentation highlights the antitumor response of VP-315 for the non-surgical treatment of Basal Cell Carcinoma (BCC) as determined by clinical and histological lesion clearance
There are approximately 3-4